Thank you very much for your feedback on this measure. The intent of this measure is to focus on antiplatelet therapy; therefore, anticoagulants should not be included in the measure. We understand that this is not clear as the measure is currently specified. For the next Annual Update, we will attempt to clarify the guidance to include only antiplatelet therapy. We will also propose adding anticoagulants as an exclusion during the next annual update. Based on discussions with our expert panel, we do not believe any other exclusions or exceptions are appropriate.

Guidance is unclear about why several examples of "another anti-thrombotic" such as Warfarin or Heparin are not included in the value set for the numerator and/or why there are no exclusions for patients who have a documented reason (e.g. intolerance) for not using the listed medications